Company intelligence / Profile preview

Halberd Corporation

Jackson Center, Pennsylvania, United States
Ownership
Private
Employees
~3
Development stage
Other
01

Overview

Halberd Corporation is developing and acquiring therapeutic and diagnostic platforms for neurodegenerative and trauma-related disorders, but there are no published clinical results or peer-reviewed outcomes as of October 2025.

Therapeutic areas
Infectious DiseasesNeurologyHematologyPsychiatryOncology
Modalities
Antibody-drug conjugateAntibodySmall moleculeExtracorporeal treatment method
Industry
Biotech
02

Drug pipeline

4 assets

Halberd COVID-19 monoclonal antibody

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Halberd Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halberd Corporation.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call